arbinger Health

arbinger Health

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.harbinger-health.com

Last Round

Series B

Apr 14, 2026

Total Funding Raised

$290M

Momentum Score

25 /100

Company Overview

Harbinger Health is a health technology company that specializes in a blood test utilizing artificial intelligence and machine learning for the early detection of cancer, allowing healthcare professionals to identify the disease before symptoms appear.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical AI, Healthcare Analytics, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Usage-Based SaaS, Services & Consulting

AI Layer

Application

Keywords

multi-cancer early detectionMCEDearly cancer detectionliquid biopsyblood-based testcancer diagnosticslaboratory developed testLDTBio-AI platformcancer screeningmachine learning diagnosticsepigenetic signaturesclinical trials

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

arbinger Health Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

arbinger Health Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BApr 14, 2026
Series BSep 28, 2023
SeedDec 7, 2021

Key People

Founding team and executive leadership

MPharm Gisela Paulsen

Chief Operating Officer

Executive Team

arbinger Health Investors

Notable investors and investment history

InvestorRounds
Pictet GroupSeries B
M&G InvestmentsSeries B
Partners InvestmentSeries B
Flagship PioneeringSeries B, Seed
M&G plcSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Models infer lung cancer progression from blood draw cfDNA methylation data.

  • Apr 14, 2026

    $100M round raised.

arbinger Health Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

arbinger Health Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about arbinger Health's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range65
Year Founded2008
Last FundingApr 14, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.